FDA Grants Neladalkib Accelerated Approval for Lung Cancer
The Food and Drug Administration granted accelerated approval on Tuesday, November 17, 2026, to neladalkib (Nelkarmi, Nuvalent, Inc.) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have already been treated. The evidence comes from ALKOVE-1, a single-arm, open-label trial with no comparison group. In 67 patients who had received alectinib as their one prior ALK inhibitor, the confirmed response rate was 49 percent. In 155 patients who had received two or more prior ALK inhibitors plus platinum chemotherapy, it was 32 percent.
Edited and fact-checked by Stephen Sprague
An accelerated approval is a conditional one. Neladalkib stays on the market while confirmatory trials test whether the tumor responses in ALKOVE-1 turn into longer survival, and the FDA can revisit the decision if they do not.
A patient whose lung cancer stopped responding to alectinib gained a new oral option on Tuesday. The FDA granted neladalkib accelerated approval for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer in the unresectable setting.
The label covers two groups. The first received one prior ALK tyrosine kinase inhibitor, and that inhibitor has to be alectinib. The second received two or more prior ALK inhibitors and platinum-based chemotherapy. Patients outside those two treatment histories aren't covered by this approval.
Neladalkib is a kinase inhibitor, and the dose is 150 mg by mouth once a day, with or without food, taken at the same time each day. Treatment continues until the disease progresses or side effects become unacceptable. For a patient already through one or more lines of therapy, a once-daily pill at home is a different daily reality from an infusion schedule.
ALKOVE-1 (NCT05384626) enrolled 222 patients across its cohorts, and a blinded independent central review measured the results. Among the 67 patients pretreated with alectinib, 49 percent saw their tumors shrink enough to count as a response. Among responders, 76 percent held that response for at least six months and 52 percent for at least 12 months.
The 155 patients who had received two or more prior ALK inhibitors plus chemotherapy responded at 32 percent. In that group, 69 percent of responders held the response for at least six months and 51 percent for at least 12 months. Heavier pretreatment tracks with a lower response rate in the same trial, and readers should hold both numbers together rather than quote the higher one alone.
ALKOVE-1 had no control arm, so the trial can't show whether neladalkib extends survival or improves symptoms against another treatment. Response rate and response duration are the whole evidence base for this approval. That limit is the reason the approval is accelerated rather than regular, and confirmatory testing is the step that decides what happens next.
The prescribing information carries warnings for liver toxicity, kidney toxicity, eye toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity. The most common side effects, each in at least 20 percent of patients, were liver toxicity, muscle pain, constipation, altered taste, peripheral neuropathy, swelling, and fatigue.
The application received priority review, and the drug holds breakthrough therapy and orphan drug designations. The FDA reviewed it with the Assessment Aid, a voluntary applicant submission that structures the agency's evaluation. None of those programs changes the central fact of the approval. It rests on tumor shrinkage in a single-arm trial, and the confirmatory record is still owed.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.